

Applicants have also added new claims 50-54 that are drawn to the subject matter of elected Group X and link the invention of Group X to the invention of the new claims.

In light of In Re Ochiai and In Re Brouwer (Official Gazette, March 26, 1996, which establishes guidelines for treatment of product and process claims), such linking claims permit joinder of claims relating to the making of a novel product or the use of a novel composition with the method of making the product or using the composition. In the present case, linking claims 50-54 use the novel nucleic acids of Group X in a method of making the novel polypeptides of Group X.


REMARKS AND CONCLUSION

Claims 1-4, 38, 41 and 50-54 are pending upon entry of this amendment. Claims 5-37, 39-40 and 42-49, directed to non-elected species, have been canceled without prejudice and without disclaimer of subject matter. Support for new claims 50-54 appear at least, *e.g.*, in the specification at page 1, lines 8-11, and from page 81, line 9, to page 85, line 32. No new matter is added.

Applicants note that the due date listed in the Status line on page 1 of the Restriction Requirement inadvertently lists the instant application's filing date as the due date for this response. Applicants believe the due date without extension should be one month from the mailing date, as noted in the Shortened Statutory Period for Reply section on page 1. Hence, with a one month extension of time and fee under 37 CFR 1.17(a)(1), this response is due on or before September 3, 2002.

The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0311, Reference No.15966-750 (CURA-250).

Respectfully submitted,



Date: September 3, 2002

Ivor R. Elrifi, Reg. No. 39,529
Kristin E. Konzak, Reg. No. 44,848
Attorney/Agent for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Appendix A - Version marked to show changes made

In the Claims:

Cancel claims 5-37, 39-40 and 42-49, directed to non-elected species, without prejudice and without disclaimer of subject matter.

Amend claims 1-3 as indicated below:

1. (Amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) a mature form of an amino acid sequence [selected from the group consisting] of SEQ ID [NOS:2, 4, 6, 8, 10, 12, 14, 16, 18 and] NO:20;
 - (b) a variant of a mature form of an amino acid sequence [selected from the group consisting] of SEQ ID [NOS:2, 4, 6, 8, 10, 12, 14, 16, 18 and] NO:20, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
 - (c) an amino acid sequence [selected from the group consisting] of SEQ ID [NOS:2, 4, 6, 8, 10, 12, 14, 16, 18 and] NO:20; and
 - (d) a variant of an amino acid sequence [selected from the group consisting] of SEQ ID [NOS:2, 4, 6, 8, 10, 12, 14, 16, 18 and] NO:20, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.
2. (Amended) The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of a naturally-occurring allelic variant of an amino acid sequence [selected from the group consisting] of SEQ ID [NOS:2, 4, 6, 8, 10, 12, 14, 16, 18 and] NO:20.
3. (Amended) The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide

from a nucleic acid [selected from the group consisting] of SEQ ID [NOS:2, 4, 6, 8, 10, 12, 14, 16, 18 and] NO:19.

Add the following new claims:

--50. (New) A method of producing the polypeptide of claim 1, the method comprising culturing a cell under conditions that lead to expression of the polypeptide, wherein said cell comprises a vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:19.

51. (New) The method of claim 50 wherein the cell is a bacterial cell.

52. (New) The method of claim 50 wherein the cell is an insect cell.

53. (New) The method of claim 50 wherein the cell is a yeast cell.

54. (New) The method of claim 50 wherein the cell is a mammalian cell. --

TRA 1706891v1